NVIDIA and QIAGEN are collaborating to bring trustworthy, contextual AI to drug discovery. By integrating NVIDIA's accelerated computing and the BioNeMo platform with QIAGEN Digital Insights' manually curated biomedical knowledge graphs, cited in over 70,000 peer-reviewed publications; the collaboration aims to transform how disease mechanisms, therapeutic targets, and biomarkers are identified. Using a graph-based AI approach built on G-Retriever, the solution delivers 5–10x better performance than standard RAG pipelines, giving researchers answers they can trust, defend, and act on. In this conversation from Bio-IT World 2026, NVIDIA's Ben Busby and QIAGEN's Venkatesh Moktali discuss what each side brings, why knowledge graphs are a must-have for pharma AI, and what's coming next — including initial pilots with select pharma and biotech partners ahead of broader availability.